Does Dupixent Help with Itching?
Yes, Dupixent (dupilumab) reduces itching in patients with moderate-to-severe atopic dermatitis (eczema), prurigo nodularis, and chronic spontaneous urticaria. Clinical trials show it lowers itch severity by blocking IL-4 and IL-13 signaling, key drivers of inflammation and itch. In eczema studies, 36-51% of patients achieved a 4-point or greater improvement in the Peak Pruritus Numerical Rating Scale (NRS) at week 16, compared to 9-15% on placebo.[1][2]
How Quickly Does It Reduce Itch?
Itch relief often starts within 2-4 weeks. In the LIBERTY AD trials, significant reductions in worst daily itch occurred by week 2, with peak effects by week 24. For prurigo nodularis, 45% of patients reported little to no itch after 24 weeks versus 18% on placebo.[3]
What Conditions Does It Target for Itch Relief?
Dupixent is FDA-approved for itch in:
- Atopic dermatitis (ages 6 months+)
- Prurigo nodularis (adults)
- Chronic rhinosinusitis with nasal polyps (reduces associated itch)
- Eosinophilic esophagitis and chronic obstructive pulmonary disease (less itch-focused but includes symptom relief)
It does not treat acute hives or non-inflammatory itch causes like dry skin alone.[4]
Common Side Effects and Itch-Related Concerns
Injection-site reactions (10-20%) and eye issues like conjunctivitis (10%) occur, but new itching is rare—less than 2%. Some patients report initial itch worsening before improvement.[5] Long-term data from open-label extensions show sustained itch reduction up to 3 years.[2]
Who Makes Dupixent and What's the Cost?
Sanofi and Regeneron co-develop and market it. List price is about $3,800-$5,000 monthly (U.S.), varying by dose; patient assistance programs lower it for eligible users.[6]
How Does It Compare to Other Itch Treatments?
| Treatment | Itch Reduction Speed | Key Difference from Dupixent |
|-----------|----------------------|-----------------------------|
| Topical steroids | Days | Faster but shorter-term; skin thinning risk |
| JAK inhibitors (e.g., Cibinqo) | 1-2 weeks | Oral; more infection risk |
| Abrocitinib (Cibinqo) | Similar | Targets JAK1; oral convenience |
| Nemolizumab (Nemluvio) | 4 weeks | IL-31 blocker; approved 2024 for prurigo |
Dupixent outperforms topicals in head-to-head trials for severe cases.[7]
When Does the Dupixent Patent Expire?
Core composition patents expire around 2031 in the U.S., with some method-of-use patents to 2035. Challenges from Amgen and others are ongoing; biosimilars unlikely before 2031.[8] Check DrugPatentWatch.com for updates.
Sources
[1] New England Journal of Medicine (2016): LIBERTY AD trial
[2] FDA Label: Dupixent (dupilumab)
[3] Lancet (2023): Prime 1/2 trials for prurigo nodularis
[4] Dupixent.com prescribing information
[5] JAAD (2020): Safety profile analysis
[6] GoodRx pricing data (2024)
[7] NEJM (2022): Comparative efficacy review
[8] DrugPatentWatch.com